Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Rhea-AI Summary
Mesa Laboratories (NASDAQ: MLAB) announced a CEO transition: Gary Owens will step down as President and CEO effective April 12, 2026, and Dr. Siddhartha Kadia will become President and CEO and join the Board effective April 13, 2026.
Dr. Kadia brings prior CEO roles at Calibre Scientific and EAG Laboratories, leadership at Life Technologies overseeing a $2 billion business, and global life-sciences experience. The company emphasized a planned, smooth leadership transition.
Positive
- New CEO Siddhartha Kadia brings global life-sciences scale experience
- Dr. Kadia previously oversaw a $2 billion business at Life Technologies
Negative
- Current CEO Gary Owens will step down effective April 12, 2026
- Leadership transition timing: one-day gap between CEO departure and new CEO start
Key Figures
Market Reality Check
Peers on Argus
MLAB was down 0.59% pre-announcement, while peers were mixed: VPG +3.15%, ITRN +2.08%, FARO +0.43%, KNW +0.47%, MVIS -3.49%. This points to stock-specific factors rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Earnings results | Positive | +8.7% | Reported Q3 FY2026 revenue growth and higher AOI with debt reduction. |
| Jan 07 | Dividend declaration | Positive | -4.1% | Announced regular quarterly dividend of $0.16 per share. |
| Dec 18 | Conference presentation | Neutral | +0.6% | Planned presentation at 44th Annual J.P. Morgan Healthcare Conference. |
| Dec 03 | Earnings date notice | Neutral | +1.0% | Scheduled Q3 FY2026 results release for February 3, 2026. |
| Nov 12 | Investor conferences | Neutral | -0.2% | Announced management participation in several investor conferences. |
Recent history shows generally positive reactions to earnings updates, while dividend and conference-related news have produced mixed price responses.
Over the last few months, Mesa reported solid operating trends and balance sheet actions. Q3 FY2026 results on Feb 3, 2026 showed revenue of $65.126M and an 8.73% next-day gain. A quarterly dividend declaration on Jan 7, 2026 saw a 4.11% decline. Conference and scheduling announcements in late 2025 produced modest, mixed moves. Against this backdrop, the CEO transition reflects a governance milestone rather than a financial update.
Market Pulse Summary
This announcement details a planned CEO transition from Gary Owens to Siddhartha Kadia in April 2026, framed as an orderly handoff after several years of growth. Historical news centered on earnings and capital allocation, while this update focuses on leadership and governance. Investors may watch upcoming earnings releases, strategic updates, and any revised priorities under the new CEO to gauge operational and financial impact over time.
Key Terms
forward-looking statements regulatory
form 10-k regulatory
form 10-q regulatory
8-k regulatory
AI-generated analysis. Not financial advice.
LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens will step down as President and CEO on April 12, 2026, and will enable a smooth leadership transition.
“Gary has served as Mesa’s CEO since 2017, leading Mesa through a period of significant growth, expansion into new markets, the maturation of the company’s foundation, and the implementation of The Mesa Way business system,” said John Sullivan, Chair of the Board. “We are grateful for his leadership and wish him continued success.”
To lead the Company’s next chapter, the Board of Directors has appointed Dr. Siddhartha Kadia as President and Chief Executive Officer, effective April 13, 2026. Dr. Kadia will also join the Board.
Dr. Sullivan added, “Siddhartha is a proven global executive with deep experience scaling life sciences businesses. His track record of commercializing innovative technologies and leading complex organizations makes him the right leader for Mesa’s next chapter.”
Dr. Kadia most recently served as CEO of Calibre Scientific and previously led PhenomeX (formerly Berkeley Lights). Earlier, he was President and CEO of EAG Laboratories, which expanded significantly before being acquired by Eurofins Scientific. He also served as President of Life Sciences at Life Technologies, overseeing a
Dr. Kadia has served on the boards of several public life sciences companies, including NuVasive, Volcano Corporation, Newport Corporation, Horizon Discovery Group, Berkeley Lights, and IsoPlexis. He holds a Ph.D. in Biomedical Engineering from the Johns Hopkins University School of Medicine, an M.S. from Rutgers University, and a B.E. from L.D. College of Engineering, Gujarat University.
“I am honored to join Mesa at this important time,” said Dr. Kadia, “I look forward to working with the talented team to build on the Company’s strong foundation and continue delivering long-term value for our customers, employees, and shareholders.”
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to leadership, strategic matters and future results. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2025, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.
CONTACT: John Sakys; CFO of Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Company, please visit its website at www.mesalabs.com
FAQ
When will Mesa Laboratories (MLAB) implement the CEO transition?
Who is the new CEO of Mesa Laboratories (MLAB) and what is his background?
What did Mesa say about Gary Owens' departure from the CEO role (MLAB)?
Will Siddhartha Kadia join Mesa Laboratories' board when becoming CEO (MLAB)?
How might the CEO change affect Mesa Laboratories' strategic direction (MLAB)?
